Epithelial-myoepithelial carcinoma is a rare cancer that usually starts in a salivary gland, most often the parotid gland near the jaw. It tends to grow slowly, and many people first notice a painless lump or swelling, so early symptoms of epithelial-myoepithelial carcinoma can be easy to miss. It is usually found in adults, especially middle-aged or older adults, and not everyone will have the same experience. Treatment most often involves surgery, and some people also need radiation therapy if the tumor is harder to remove or has higher-risk features. Epithelial-myoepithelial carcinoma can come back after treatment and can sometimes spread, but many people do well when it is found early and treated carefully.
How many people live with Epithelial-myoepithelial carcinoma?
Global and U.S. estimates for how many people are living with epithelial-myoepithelial carcinoma are not consistently reported by a single authoritative source. This cancer is very rare, and the medical literature usually describes it as an uncommon subtype of salivary gland cancer rather than giving a reliable worldwide or U.S. count of people living with it.
Overview
Epithelial-myoepithelial carcinomaSymptoms
Epithelial-myoepithelial carcinoma often starts as a slow-growing, usually painless lump in a salivary gland, often near the jaw or ear. Some people also notice swelling, discomfort, trouble swallowing, or weakness in the face.
Outlook and prognosis
Epithelial-myoepithelial carcinoma often grows slowly, so many people do well after surgery, especially when it is found before it has spread. Long-term follow-up matters because this cancer can come back years later, and outlook is poorer if it returns or spreads.
Causes and risk factors
The exact cause of epithelial-myoepithelial carcinoma is usually unknown. Risk may rise with older age and prior radiation to the head or neck. No clear lifestyle or inherited genetic risk has been proven.
Genetic influences
Genetics matter in epithelial-myoepithelial carcinoma, but no single inherited cause is known for most people. This cancer usually develops from acquired DNA changes in the tumor itself rather than from variations passed down through families.
Diagnosis
Epithelial-myoepithelial carcinoma is diagnosed after a biopsy confirms the tumor under the microscope. Imaging such as CT, MRI, or ultrasound helps show its size, exact location, and whether it has spread.
Treatment and drugs
Epithelial-myoepithelial carcinoma is usually treated with surgery to remove the tumor, often followed by radiation if margins are close or it has spread nearby. Care may also include scans and regular follow-up to watch for recurrence.
Symptoms
Epithelial-myoepithelial carcinoma often shows up as a slow-growing lump, most often in a salivary gland near the ear or jaw. It may stay painless for a while, which can make the early symptoms of epithelial-myoepithelial carcinoma easy to miss. Symptoms vary from person to person and can change over time. As the tumor grows, it can press on nearby tissues and cause discomfort, facial changes, or trouble chewing or swallowing.
The most common symptom is a firm lump or swelling near the ear, jaw, or inside the mouth. It often gets bigger slowly over weeks or months and may not hurt at first.
Some people feel aching, tenderness, or a sense of pressure in the area as the tumor grows. Day to day, it can feel like soreness when touching the lump or lying on that side.
If the tumor affects nearby nerves, one side of the face may feel weak, numb, or less coordinated. Some people notice a crooked smile, trouble closing one eye, or drooling from one side.
A growth near the jaw or salivary glands can make chewing uncomfortable or make the jaw feel tight. Some people also have trouble swallowing, especially if the tumor is deeper in the mouth or throat.
How people usually first notice Epithelial-myoepithelial carcinoma?
People usually first notice epithelial-myoepithelial carcinoma as a slow-growing, painless lump, most often near the jaw or just in front of the ear where the salivary glands sit. Because it often grows quietly, many living with this cancer do not feel ill at first, but some may notice swelling, a sense of fullness, discomfort, facial weakness, or trouble swallowing if the mass presses on nearby nerves or tissues. These early warning signs are not specific and can overlap with noncancerous salivary gland problems, which is why a new lump in this area should be checked by a clinician.
Types of Epithelial-myoepithelial carcinoma
Epithelial-myoepithelial carcinoma can show up in a few recognized variants under the microscope, and those variants may affect how fast the cancer grows or how likely it is to come back. In day-to-day life, though, symptoms often depend more on where the tumor is than on the exact subtype. Many people notice a slow-growing lump near a salivary gland, while more aggressive variants are more likely to cause pain, faster enlargement, or nearby nerve problems. For people wondering about the types of epithelial-myoepithelial carcinoma, the main differences are usually in tumor behavior rather than completely different symptom patterns.
Classic type
This is the usual form and often appears as a slow-growing, painless lump, most often in the parotid salivary gland near the jaw or ear. Some may find it has been there for months before it is noticed. Symptoms don’t always look the same for everyone.
Oncocytic variant
This less common variant has cells with a different appearance under the microscope, but it often causes symptoms much like the classic type. Many living with this form still notice a mass or swelling rather than clearly distinct warning signs.
Sebaceous variant
This rare variant can also present as a salivary gland lump, and symptoms are usually similar to other forms of epithelial-myoepithelial carcinoma. In most cases, the subtype is identified after imaging and biopsy rather than from symptoms alone.
High-grade transformation
This more aggressive variant tends to grow faster and is more likely to cause pain, facial weakness, or trouble from pressure on nearby tissues. Even within the same type, intensity can range from mild to severe. Doctors usually take this form more seriously because it may spread or return more readily.
Can I slow down the onset of symptoms?
No one has shown that lifestyle changes or medicines can meaningfully delay the start of symptoms in epithelial-myoepithelial carcinoma, a rare cancer that usually begins in a salivary gland, and there is no proven way to prevent it. Because it is so rare, research is limited; general healthy habits like not smoking and keeping up with routine medical and dental care support overall health, but they have not been shown to reduce the risk of this cancer in a clear, proven way, and there is no standard screening test or preventive medicine for people without symptoms. What can help is having a new lump near the jaw, mouth, or neck checked early, since early diagnosis may improve treatment choices even though it cannot guarantee a better outcome.
What genetics can tell you about symptoms
In epithelial-myoepithelial carcinoma, genetic changes inside the tumor can help explain how the cancer develops, but they usually do not predict day-to-day symptoms in a clear way. Some tumors carry changes in genes such as HRAS, and these may be linked to tumor behavior in some cases, but doctors generally cannot use them to reliably tell which symptoms will show up, how severe they will be, or exactly when they will begin. For most people living with this cancer, symptoms are shaped more by where the tumor grows and how large it becomes than by a specific genetic finding.
Causes and risk factors
For many people with epithelial-myoepithelial carcinoma, the biggest question is what caused it. In most cases, the exact causes of epithelial-myoepithelial carcinoma are unknown, but it seems to begin when salivary gland cells pick up DNA changes over time. This rare cancer is seen most often in older adults, and it may affect women slightly more often than men. Past radiation treatment to the head or neck may raise the risk, but no clear lifestyle cause has been proven. Researchers are still learning how these pieces fit together, and most cases are not linked to an inherited gene change or a strong family history.
What are the most common causes or risk factors?
There is no single known cause of epithelial-myoepithelial carcinoma, and many people living with it have no clear risk factor. It is seen most often in older adults, usually starts in a salivary gland, and in some cases it develops from a long-standing noncancerous salivary gland lump. Changes in genes that control cell growth, especially a gene called HRAS, are found in some tumors, and prior radiation to the head or neck may also raise the risk.
Environmental and biological risk factors
Epithelial-myoepithelial carcinoma is a very rare salivary gland cancer, so its risk factors are not mapped as clearly as they are for more common cancers. That said, biology and environment work hand in hand. When people search for risk factors for epithelial-myoepithelial carcinoma, the clearest links are older age and prior radiation to the head and neck, while many cases happen without an obvious cause.
Epithelial-myoepithelial carcinoma is seen most often in middle-aged and older adults, especially later adulthood. It is uncommon in children and younger adults.
Studies have found epithelial-myoepithelial carcinoma somewhat more often in women than in men. This is only a pattern in who gets the cancer more often, not a sign that it is expected to occur.
Previous radiation exposure to the head and neck can raise the risk of salivary gland cancers, including rare types such as epithelial-myoepithelial carcinoma. This increased risk may appear many years after radiation treatment or other significant exposure.
Genetic risk factors
For most people with epithelial-myoepithelial carcinoma, the key genetic changes are ones that develop in the tumor itself over time, not changes clearly inherited from a parent. The genetic causes of epithelial-myoepithelial carcinoma are still being worked out because this cancer is rare, but a few patterns are well recognized. HRAS changes are among the most common findings, and some tumors carry gene rearrangements linked to an earlier benign salivary gland growth. So far, no strong inherited family syndrome has been firmly tied to most cases.
Somatic changes: In most cases, the important DNA changes arise only in the tumor and are not present in the rest of the body. This means the cancer usually starts from gene mistakes that happened in salivary gland cells during life, rather than from a clearly inherited change.
HRAS mutations: Changes in the HRAS gene are among the most common genetic findings in epithelial-myoepithelial carcinoma. HRAS normally helps control cell growth, and an altered version can keep growth signals too active.
PLAG1 or HMGA2: Some epithelial-myoepithelial carcinomas develop from a preexisting pleomorphic adenoma, which is a benign salivary gland tumor. In these cases, rearrangements involving PLAG1 or HMGA2 may be found and support that earlier tumor origin.
Inherited risk: A well-defined inherited syndrome has not been established for most people with epithelial-myoepithelial carcinoma. For many families, this means relatives are not known to have a large genetic risk based on this diagnosis alone.
Lifestyle risk factors
For epithelial-myoepithelial carcinoma, direct research on lifestyle risk factors is limited because this is a rare salivary gland cancer. Still, some everyday habits may influence cancer risk in general and may be relevant when thinking about lifestyle risk factors for epithelial-myoepithelial carcinoma. The strongest lifestyle-related concerns are tobacco use, alcohol use, diet quality, excess body weight, and low physical activity. These factors are not proven causes in every case, but they can affect overall cancer risk and long-term health.
Smoking and other tobacco use may increase the chance of cellular injury in tissues of the head and neck. Over time, this kind of repeated damage can contribute to cancer development and may be relevant to salivary gland tumors.
High alcohol intake can irritate tissues and adds to the overall burden of cancer risk. When combined with smoking, its harmful effects on head and neck tissues may be even greater.
A diet low in fruits, vegetables, and fiber may reduce intake of nutrients that help protect cells from oxidative damage. Diets high in ultra-processed foods and excess calories may also support chronic inflammation, which is linked with cancer risk.
Overweight and obesity can promote hormonal and inflammatory changes that may favor cancer development. Maintaining a healthier body weight may help lower overall cancer risk, even though evidence specific to this tumor is limited.
Risk prevention
There is no sure way to prevent epithelial-myoepithelial carcinoma, and many people who develop it do not have a clear avoidable cause. Still, some steps may help lower the risk of salivary gland cancers in general and support earlier care if something changes. Prevention is about lowering risk, not eliminating it completely. Paying attention to new swelling near the jaw or in the mouth can also help people act sooner if early symptoms of epithelial-myoepithelial carcinoma appear.
Not smoking and avoiding smokeless tobacco may help reduce the risk of several head and neck cancers, including cancers that can affect the salivary glands. If you use tobacco now, quitting can still benefit your long-term health.
Heavy alcohol use is linked to some cancers in the head and neck region, so cutting back is a sensible risk-reduction step. Keeping drinking moderate or avoiding it altogether may be especially helpful when combined with not smoking.
Limiting unnecessary radiation exposure to the head and neck may lower risk over time. When imaging tests or treatments are needed, doctors aim to use the lowest amount that still gives safe, accurate care.
Some jobs involve dusts, chemicals, or industrial exposures that may raise cancer risk, although links to epithelial-myoepithelial carcinoma are not firmly defined. Using protective equipment and following workplace safety rules can help reduce avoidable exposure.
Can you prevent Epithelial-myoepithelial carcinoma?
There is no known, proven way to prevent epithelial-myoepithelial carcinoma, a rare cancer that usually starts in a salivary gland, because its exact cause is still not clear. In general, avoiding tobacco and getting new swelling or a lump near the jaw, mouth, or neck checked early may help protect overall health, but these steps have not been shown to reliably prevent this specific cancer.
Transmission
Epithelial-myoepithelial carcinoma is not infectious, so it cannot be caught from someone else through the air, close contact, sex, food, or blood. It is not spread by kissing, sharing utensils, touching, or caring for someone who has it.
Many living with Epithelial-myoepithelial carcinoma also worry about family risk, but in most cases this cancer is not known to be passed from parent to child, so questions about how Epithelial-myoepithelial carcinoma is inherited usually have a reassuring answer. It typically develops because of gene changes that happen in salivary gland cells during life, rather than from an infection or something another person can transfer to you.
When to test your genes
For epithelial-myoepithelial carcinoma, routine inherited gene testing is not usually used for early detection, because this is a rare salivary gland cancer without a well-established screening gene. Genetic testing may be considered on the tumor itself if the cancer is recurrent, metastatic, or diagnostically unclear, and inherited testing may matter if there is a strong family history of related cancers.
Diagnosis
Epithelial-myoepithelial carcinoma is usually diagnosed after a slow-growing lump, often near the jaw or in a salivary gland, leads to medical evaluation. Because it is rare and can look like other salivary gland tumors, the diagnosis of epithelial-myoepithelial carcinoma often depends on tissue testing rather than symptoms alone. Doctors usually begin with an exam of the area and imaging to see the size of the tumor and whether nearby structures are involved.
Your doctor asks when the lump was first noticed, whether it has grown, and if there is pain, numbness, trouble swallowing, or facial weakness. They also examine the mouth, jaw, neck, and salivary glands for swelling or enlarged lymph nodes.
Ultrasound, CT, or MRI can show where the tumor starts and how far it extends into nearby tissues. These scans help plan the safest place to sample the mass and may guide treatment decisions later.
A fine-needle aspiration or core needle biopsy removes a small sample from the lump for testing. This is often the key step in how epithelial-myoepithelial carcinoma is diagnosed, although a small sample may not always give a definite answer.
A pathologist studies the tissue under a microscope to look for the typical two-cell pattern seen in this cancer. Because other salivary gland tumors can appear similar, the final diagnosis may sometimes be made only after surgery removes more tissue.
How is Epithelial-myoepithelial carcinoma diagnosed?
Epithelial-myoepithelial carcinoma is usually diagnosed after a doctor checks the lump, asks about symptoms, and uses scans such as an ultrasound, CT scan, or MRI to see where it is and how big it is. The diagnosis is confirmed by a biopsy, which means taking a small piece of tissue, or by testing tissue removed during surgery and looking at it under a microscope; special lab stains may also be used to tell it apart from other salivary gland tumors. Genetic testing is not usually the main way this cancer is diagnosed, but it may sometimes be used to add information in unclear cases.
Stages of Epithelial-myoepithelial carcinoma
Epithelial-myoepithelial carcinoma is usually described by cancer stage, which tells you how large the tumor is and whether it has spread. This matters because the stage helps guide treatment and gives a clearer idea of what doctors are watching for over time. In many people, early symptoms of epithelial-myoepithelial carcinoma can be subtle, such as a slow-growing lump near a salivary gland, most often around the parotid area near the jaw and ear.
Stage 1
The tumor is small and limited to where it started. It has not spread to nearby lymph nodes or to other parts of the body.
Stage 2
The tumor is larger than in stage 1 but is still confined to the original area. There is still no spread to lymph nodes or distant organs.
Stage 3
The cancer may be larger or may have started to involve a nearby lymph node on the same side. Some people also have signs that it is affecting nearby tissues more deeply.
Stage 4
The cancer is more advanced and may be growing into nearby structures such as skin, bone, nerves, or deeper tissues. It may also have spread to multiple lymph nodes or to distant parts of the body, such as the lungs.
Outlook and prognosis
The outlook for epithelial-myoepithelial carcinoma is often relatively favorable compared with many other salivary gland cancers because it is usually a low-grade tumor that tends to grow slowly. However, prognosis varies with tumor size, location, completeness of surgical removal, and whether there is local invasion, recurrence, or spread to lymph nodes or distant sites. Local recurrence is not uncommon, sometimes occurring years after initial treatment, so long-term follow-up is important even after apparently successful surgery. Most people do well when the cancer is found early and fully removed, but more aggressive or high-grade transformed cases have a worse outlook. Death from epithelial-myoepithelial carcinoma is uncommon overall, yet mortality risk increases in advanced, recurrent, or metastatic disease.
Long-term effects
For many people, the long-term picture with epithelial-myoepithelial carcinoma depends most on where the tumor started, whether it can be fully removed, and whether it comes back after treatment. This cancer often grows slowly, but it can still cause lasting problems in the area around the salivary gland and, in some cases, spread later on. Long-term effects vary widely, and some people do well for years with careful follow-up. Thinking about the long-term effects of epithelial-myoepithelial carcinoma helps explain why doctors may monitor it over time.
Epithelial-myoepithelial carcinoma can come back in the same area months or years after treatment, even when it seemed fully treated at first. This is one of the main long-term concerns because repeat growth can affect nearby tissues and sometimes lead to more treatment.
When this cancer affects a salivary gland, many living with epithelial-myoepithelial carcinoma may have ongoing dry mouth or reduced saliva, especially if the gland was removed or damaged. Over time, this can make eating dry foods, speaking for long periods, and dental health more difficult.
Some may find that long-term stiffness, discomfort, or swelling around the jaw and cheek changes how easily they chew or open their mouth. If nearby muscles or soft tissues are affected, everyday things like smiling for a photo or eating a sandwich can feel less comfortable.
If the tumor grows near facial nerves, it can sometimes lead to lasting weakness, numbness, or changes in facial movement. For some, this may affect blinking, smiling, or feeling on one side of the face.
How is it to live with Epithelial-myoepithelial carcinoma?
Living with epithelial-myoepithelial carcinoma often means coping with uncertainty as much as with the tumor itself, because this rare salivary gland cancer may grow slowly yet still require surgery, and sometimes radiation, that can affect comfort, energy, appearance, chewing, swallowing, or facial movement depending on where the tumor sits. In daily life, many people are balancing medical visits, recovery time, and the emotional strain of hearing that a cancer is uncommon, which can make it harder to find familiar stories or support. Family and close friends are often drawn into appointments, caregiving, and reassurance, so the condition can ripple through work, routines, and relationships, even while many people continue much of their usual life between treatment and follow-up.
Treatment and drugs
Epithelial-myoepithelial carcinoma is usually treated first with surgery to remove the tumor, because this cancer often grows in a salivary gland and can come back if any cells are left behind. After surgery, doctors may recommend radiation therapy, especially if the tumor is large, has close or positive margins, or shows signs of spreading into nearby tissue or nerves. Treatment often looks different for each person, and if the cancer has spread or returns after initial care, specialists may consider additional surgery, radiation, or sometimes drug treatment such as chemotherapy, although medicines tend to have a more limited role than surgery. Because epithelial-myoepithelial carcinoma is rare and can vary in behavior, follow-up visits and scans are an important part of care so early signs of recurrence can be caught and treated promptly.
Can you cure Epithelial-myoepithelial carcinoma?
Sometimes. When epithelial-myoepithelial carcinoma is found early and can be completely removed, treatment, usually surgery and sometimes radiation, can cure it, but there is no guaranteed cure and it can come back even years later. If it has spread or returns after treatment, care usually focuses on controlling the cancer, slowing its growth, and managing symptoms.
Non-drug treatment
For many living with epithelial-myoepithelial carcinoma, treatment often centers on procedures rather than medicines, especially because this rare salivary gland cancer is usually managed locally. The main goal is to remove or control the tumor while protecting speaking, swallowing, eating, and comfort as much as possible. Supportive therapies can also help during recovery and follow-up, since some people need extra care for dry mouth, stiffness, or changes in chewing and speech.
Surgery is usually the main treatment for epithelial-myoepithelial carcinoma, especially when the tumor can be fully removed. This often means taking out the cancer with a rim of healthy tissue, and sometimes removing part or all of a salivary gland and nearby lymph nodes if spread is a concern.
Radiation may be used after surgery when margins are close, the tumor is larger, or the cancer has features linked with a higher chance of coming back. For some people who cannot have surgery, it can also be used to help control the disease locally.
If surgery affects the face, mouth, or jaw area, reconstructive procedures may help restore appearance and everyday function. This can make it easier to chew, speak clearly, and feel more comfortable in daily life.
Treatment in the head and neck area can leave some people with trouble swallowing, voice changes, or jaw tightness. Structured programs, like speech and swallowing therapy, can help rebuild strength, improve safety with eating, and support recovery after treatment.
Your genes may have an impact on how drugs work for you
For epithelial-myoepithelial carcinoma, treatment is usually centered on surgery, and sometimes radiation, so there are no well-established everyday drug choices where inherited gene differences are known to clearly change how the medicine works. If the cancer comes back or spreads and drug treatment is considered, doctors may sometimes test the tumor itself to look for changes that could help guide care, but this is not routine and does not yet give clear, standard answers for most people living with this rare cancer. In short, gene-based medication matching is not a usual part of care for this condition right now.
Pharmacological treatments
Drug treatment is not the main approach for epithelial-myoepithelial carcinoma, and many people never need cancer medicines at all because surgery is usually the key treatment. When the cancer has spread, comes back, or cannot be removed fully, doctors may consider medicines that are more commonly used for other salivary gland cancers. There is no single standard drug plan for treatment for advanced epithelial-myoepithelial carcinoma, so care is usually individualized. Not everyone responds to the same medication in the same way.
Cisplatin or carboplatin may be used when epithelial-myoepithelial carcinoma is recurrent, metastatic, or not suitable for surgery. These medicines are often given with another chemotherapy drug rather than used alone.
Paclitaxel or docetaxel may be paired with a platinum drug to help slow tumor growth in advanced epithelial-myoepithelial carcinoma. This approach is borrowed from treatment plans used for other salivary gland cancers because strong EMC-specific data are limited.
5-fluorouracil, often called 5-FU, and the related oral drug capecitabine are sometimes used in combination chemotherapy. They may be considered when doctors want a broader drug regimen for disease that has spread or returned.
Some specialists may use multi-drug regimens that include cyclophosphamide, doxorubicin, or vinorelbine in selected cases. Because epithelial-myoepithelial carcinoma is rare, these choices are usually based on small case series and individual treatment goals.
Genetic influences
In epithelial-myoepithelial carcinoma, genetics seem to matter mainly inside the tumor rather than through traits passed down in families. Most people with epithelial-myoepithelial carcinoma do not have a known inherited cancer syndrome, so a strong family history is usually not part of the picture. Instead, researchers have found acquired gene changes in the cancer cells themselves, especially in a gene called HRAS; a change in a gene can sometimes affect health by pushing cells to grow when they should not. Some tumors also show changes in pathways involving PIK3CA or AKT1, and a smaller number may carry gene changes linked to an earlier benign salivary gland tumor. For many living with epithelial-myoepithelial carcinoma, this means genetic testing is more often done on the tumor tissue than with a blood test looking for an inherited condition. These genetic changes in epithelial-myoepithelial carcinoma may help confirm the diagnosis and, in some cases, guide treatment decisions, although this cancer is rare and testing does not always change care.
Is Epithelial-myoepithelial carcinoma genetic?
Genetics matter in epithelial-myoepithelial carcinoma, but no single inherited cause is known for most people. This cancer usually develops from acquired DNA changes in the tumor itself rather than from variations passed down through families.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are common in the general population and are a normal part of human biology. Most do not directly affect health and simply reflect natural human diversity. In many genes, having a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when several genes and environmental factors are involved. In some situations, though, a single well-understood variant in a particular gene is enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many people living with epithelial-myoepithelial carcinoma, treatment is shaped more by where the tumor is, whether it can be fully removed, and whether it has come back than by genetics alone. Surgery is usually the main treatment, and some may also need radiation, so there often is not a standard drug plan where inherited gene testing clearly changes care. If the cancer spreads or returns and medicines are being considered, genetic testing can sometimes identify changes in the tumor that may help doctors look for a matching targeted treatment or a clinical trial. In epithelial-myoepithelial carcinoma, changes in genes such as HRAS have been found in some tumors, but this does not yet mean there is one proven drug that works for everyone with that result. Because this cancer is rare, doctors often use tumor genetics as one piece of the puzzle rather than a yes-or-no answer. This means the best treatment for epithelial-myoepithelial carcinoma is usually individualized, using the tumor’s genetic findings alongside pathology results, imaging, and your overall health.
Interactions with other conditions
Epithelial-myoepithelial carcinoma usually affects the salivary glands, and for many living with it, the main issue is not that it strongly interacts with common chronic illnesses, but that it can look similar to other salivary gland conditions. For example, a slow-growing lump near the jaw or ear can resemble a benign tumor at first, so the early symptoms of epithelial-myoepithelial carcinoma may be mistaken for a less serious gland problem. It can also develop within a pleomorphic adenoma, which is a more common noncancerous salivary gland tumor, so doctors often study the tissue closely to tell whether one condition is present, the other, or both together. Another important aspect is how it may link with other diseases. If the tumor grows into nearby nerves or tissues, symptoms may overlap with other causes of facial weakness, pain, or trouble swallowing, which can delay diagnosis. Unlike some cancers, epithelial-myoepithelial carcinoma is not known for broad, predictable disease interactions across the body, but careful follow-up matters because recurrence or spread can affect the lungs, lymph nodes, or nearby structures.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Epithelial-myoepithelial carcinoma?
Other salivary gland problems can look a lot like epithelial-myoepithelial carcinoma, especially a common noncancerous salivary gland tumor called pleomorphic adenoma and other salivary gland cancers such as adenoid cystic carcinoma or mucoepidermoid carcinoma. A blocked or infected salivary gland, or a swollen lymph node near the jaw or ear, can also cause a lump, pain, or swelling that seems similar at first. Because these conditions can overlap so much, doctors usually need imaging and a small tissue sample to tell them apart.
History
People living with epithelial-myoepithelial carcinoma are often first dealing with a slow-growing lump, usually near a salivary gland, long before they ever hear the name. In day-to-day life, this can mean noticing a painless swelling near the jaw or below the ear that seems easy to ignore at first, especially if it changes very slowly over months.
This cancer entered the medical literature relatively late compared with many more common tumors. First described in the medical literature as a distinct salivary gland cancer in the 1970s, it was recognized because pathologists began to notice a very specific pattern under the microscope: two different-looking layers of tumor cells growing together. That helped separate epithelial-myoepithelial carcinoma from other salivary gland tumors that can look similar at first glance.
As medical knowledge improved, doctors also learned that epithelial-myoepithelial carcinoma usually behaves as a low-grade cancer, meaning it often grows more slowly than many other cancers. Even so, the history of this condition has shown that “slow-growing” does not always mean harmless. Over time, reports made it clear that some tumors can come back after treatment, and a smaller number may spread, which is why careful follow-up became an important part of care.
Over the years, the way the condition has been understood has changed as more cases were collected from hospitals and cancer centers. Earlier descriptions were based mostly on what the tumor looked like under the microscope, while later research added imaging, surgical outcomes, and broader studies of long-term results. Researchers also later identified a genetic basis in at least some cases, which helped confirm that this was a true, distinct cancer type rather than just a variant of another tumor.
Today, the history of epithelial-myoepithelial carcinoma is still being written because it remains uncommon. That rarity matters: many people with epithelial-myoepithelial carcinoma may never have heard of it before diagnosis, and even experienced doctors may see only a small number of cases in a career. Knowing this history helps explain why diagnosis can take time and why specialists often review the biopsy carefully when the early symptoms of epithelial-myoepithelial carcinoma seem mild or nonspecific.